Observational studyThe Journal of infectious diseases2025
Human Metapneumovirus Epidemiology Among Middle-aged and Older Adults Hospitalized With Acute Respiratory Infection.
Observational study in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01517191 (Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Hospitalisation Burden of Human Metapneumovirus and Respiratory Syncytial Virus in Adults by Age and Comorbidity Status in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Clinical Outcomes and Molecular Epidemiology of Human Metapneumovirus in Romanian Hospitalized Patients.Microorganisms · 2026Article
- Human Metapneumovirus-associated Hospital Burden in Older Adults in Scotland: A Retrospective Analysis.Open forum infectious diseases · 2026Article
- Review: Knowledge Gained and Gaps in Understanding in the 25 Years Since Human Metapneumovirus Was First Identified as a Cause of Human Disease.The Journal of infectious diseases · 2025Review
- Association between indoor ventilation frequency and frailty among Chinese older adults.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHuman metapneumovirus (hMPV) significantly impacts young children, older adults, and those with preexisting conditions. This study examines frailty and clinical outcomes in middle-aged and older adults hospitalized due to hMPV infections.
methodsData from the Canadian Immunization Research Network's Serious Outcomes Surveillance Network were analyzed. Included were adults aged ≥50 with lab-confirmed hMPV infection. Severe infection was marked by pneumonia, oxygen need, intensive care unit admission, mechanical ventilation, or death within 30 days. The Frailty Index (FI) categorized individuals as nonfrail (FI < 0.08), prefrail (FI ≥ 0.08, FI < 0.21), and frail (FI ≥ 0.21). Multivariate ridge regression identified factors linked to disease severity.
resultsAmong 212 patients (median age 76), 85.4% had severe disease and 61.3% were frail. Frail patients had higher rates of severe disease (80.8% vs. 63.4%), oxygen therapy need (80.8% vs. 63.4%), and longer hospital stays (median 8 vs. 4 days) than patients who were nonfrail. Any cardiac illness (odds ratio [OR], 1.76; 95% confidence interval [CI], 1.02-3.09), congestive heart failure (OR, 1.91; 95% CI, 1.12-3.09), chronic obstructive pulmonary disease (OR, 1.93; 95% CI, 1.14-3.35), and frailty (OR, 1.99; 95% CI, 1.18-3.38) were significantly associated with increased odds of severe disease.
conclusionsFrailty, assessable with standardized tools, is associated with severe hMPV infections in middle-aged and older adults. Recognizing frailty in clinical management and as a vaccination criterion is necessary as hMPV vaccines become available. CLINICAL TRIALS REGISTRATION: NCT01517191 (ClinicalTrials.gov).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.